Efficacy of Human albumin in prevention of hypotension during hemodialysis in critically ill patients with low albumin

Efficacy of Human Albumin in prevention of Intradialytic Hypotension in critically ill patients with Hypoalbuminemia undergoing Hemodialysis-A Randomized Controlled Trial. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055384

Enrollment

205

Registered

2023-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N17- Acute kidney failure Health Condition 2: N18- Chronic kidney disease (CKD)

Interventions

Intervention1: 20% Human Albumin: 100 ml of 20% Human Albumin will be given over 30-60 mins at initiation of Hemodialysis Control Intervention1: Standard of care: Only standard of care as per institut

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult critically ill patients with AKI or Acute on CKD requiring Hemodialysis And 2. Patients with serum Albumin less than 2.5 gm/dl

Exclusion criteria

Exclusion criteria: 1. Refusal for consent to participate in the study 2. Patients with other clinical condition(s) requiring albumin as therapy: a. Spontaneous bacterial peritonitis b. Large volume paracentesis c. Hepatorenal syndrome

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of human albumin in preventing Intradialytic hypotension in critically ill patients with hypoalbuminemia undergoing haemodialysis. Timepoint: 4 hours	—

Secondary

Measure	Time frame
1.To compare the fluid removal in ml/kg/hour. 2.To compare the vasopressor requirementTimepoint: 4 hours	—

Countries

India

Contacts

Public ContactDR RAKESH KUMAR MOHAPATRA

AIIMS Bhubaneswar

genmed_debananda@aiimsbhubaneswar.edu.in8763290804

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026